FDA approves first radioligand generic, setting up rivalry with Novartis

For the first time, Novartis’ leadership in the radioligand field will be tested by a generic rival. Curium announced on Monday that the FDA has approved its “radioligand equivalent” to Novartis’ Lutathera for the treatment ...